Depatuxizumab mafodotin
- Generic Name
- Depatuxizumab mafodotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1585973-65-4
- Unique Ingredient Identifier
- F3R7A4P04N
- Background
Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
- Indication
No approved indication.
- Associated Conditions
- -
- Associated Therapies
- -
UNITE Study: Understanding New Interventions With GBM ThErapy
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT03419403
- Locations
- 🇩🇪
Universitatsklinikum Tubingen /ID# 169965, Tuebingen, Germany
🇺🇸Levine Cancer Ins, Carolina Me /ID# 171271, Charlotte, North Carolina, United States
🇳🇱Vrije Universiteit Medisch Centrum /ID# 170152, Amsterdam, Netherlands
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02855359
- Locations
- 🇵🇷
Ponce Medical School Foundation, Ponce, Puerto Rico
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02592876
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
- Conditions
- Interventions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 691
- Registration Number
- NCT02573324
- Locations
- 🇺🇸
Piedmont Hospital /ID# 145892, Atlanta, Georgia, United States
🇺🇸Emory Midtown Infectious Disease Clinic /ID# 144015, Atlanta, Georgia, United States
🇺🇸University of Pennsylvania Medical Center - Shadyside /ID# 144159, Pittsburgh, Pennsylvania, United States
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 266
- Registration Number
- NCT02343406
- Locations
- 🇫🇷
Hopital Pitie Salpetriere /ID# 145887, Paris, France
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy
🇫🇷CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.